Skip to content
drillr.ai
Sign up

BYSI

BeyondSpring Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.51
−8.28%
Ask drillr

  • Oct 2, 2026, 20:41 UTC

    BeyondSpring Inc. received a Nasdaq notice dated September 29, 2026 that it no longer meets the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2), giving it until March 29, 2027 to regain compliance.

  • Sep 29, 2026, 11:06 UTC

    BeyondSpring Inc. sold its wholly owned subsidiary BeyondSpring Ltd. to Biolin Investment Limited under a Share Purchase and Collaboration Agreement, with the investor to fund and complete the China portion of the DUBLIN-4 Phase 3 trial.

  • Sep 29, 2026, 11:06 UTC

    BeyondSpring Inc. entered into an Open Market Sale Agreement with Citizens JMP Securities, LLC to sell up to 9,200,000 ordinary shares through an at-the-market offering program.

  • Sep 29, 2026, 11:01 UTC

    The U.S. Food and Drug Administration granted Fast Track designation to BeyondSpring's Plinabulin plus docetaxel for advanced or metastatic non-squamous NSCLC without actionable genomic alterations that progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.

    Source:

  • Sep 18, 2026, 20:32 UTC

    BeyondSpring Inc. received a NASDAQ notice dated September 17, 2026 that it no longer complies with the $1.00 minimum bid price requirement under Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.

  • Aug 14, 2026, 21:15 UTC

    BeyondSpring reported its second-quarter 2026 financial results and provided a corporate update.

    Source:

  • Jun 4, 2026, 00:00 UTC

    Lan Huang departed as CEO of BeyondSpring Inc. effective July 1, 2026, and Min Qiu was appointed as successor CEO on the same date.

    Source: